Nightingale Health, the Finnish innovator of an internationally recognized blood biomarker technology for studying chronic diseases, will perform large-scale metabolic profiling of the Mexico City Prospective Study cohort by analyzing the biomarker profiles of blood samples from a cohort of 150,000 study participants.
Until recently, technological constraints and prohibitive costs have prevented the analysis of comprehensive biomarker data from large-scale population collections.
Jonathan Emberson, Associate Professor, Medical Statistics and Epidemiology in the Nuffield Department of Population Health, said: "The Mexico City Prospective Study provides researchers with a unique opportunity to investigate the major causes of death in a Hispanic population.
Biomarker profiling will allow us to better understand how lifestyle, environment and genetics combine to cause diseases such as cardiovascular disease in a population with high levels of obesity and diabetes."
"The chronic disease burden is global.
Therefore, it's essential to study populations across the globe capturing ethnic and socio-economic differences that underlie disease risk," said Teemu Suna, CEO and Founder, Nightingale Health.